News | Radiopharmaceuticals and Tracers | June 05, 2019

BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method

Novel technique enables simultaneous production of molybdenum-99 and other isotopes without the need for highly enriched, weapons-grade uranium

BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method

June 5, 2019 – BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for producing radioisotopes for nuclear medicine and medical imaging technologies such as computed tomography (CT) scan and positron emission tomography-computed tomography (PET-CT).

Developed by Alexander Tsechanski, Ph.D., from the BGU Department of Nuclear Engineering, the new technique obviates the need for highly enriched, weapons-grade uranium and a nuclear reactor. Nuclear medicine often necessitates the use of technetium-99m (Tc-99m) as the isotope for imaging, an unstable technetium isotope with a only a six-hour half-life that requires onsite production. In order to produce it in an economically efficient way, currently it requires weapons-grade, highly enriched uranium and a nuclear reactor to generate molybdenum-99 (Mo-99), which decays into technetium-99m (Tc-99m).

The new invention uses the naturally occurring and stable molybdenum-100 (Mo-100) isotope and a linear electron accelerator to generate Mo-99 and Tc-99m1. This process can also simultaneously generate other short-lived radioisotopes such as F-18, O-15, N-13 and C-11 as byproducts for use in PET scans.

BGN Technologies said it is currently looking for partners for further developing and commercializing the technology.

For more information: www.in.bgu.ac.il

Related Radiopharmaceuticals Content

Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes

FDA Clears Path for First Domestic Supply of Tc-99m Isotope

Reference

1. Fedorchenkoa D.V. and Tsechanski A. Photoneutronic aspects of the molybdenum-99 production by means of electron linear accelerators. Nuclear Inst. and Methods in Physics Research B, published online Oct. 23, 2018. https://doi.org/10.1016/j.nimb.2018.10.018

Related Content

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.

News | PET Imaging | May 05, 2021
May 5, 2021 — For patients with brain metastases, amino acid ...
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).

Getty Images

News | PET Imaging | April 19, 2021
April 19, 2021 — Molecular Targeting Technologies, Inc.
The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen

The inflamed joints of a rheumatoid arthritis patient are clearly visible in the PET images with the novel 68Ga-DOTA-Siglec-9 radiopharmaceutical. Image courtesy of Anne Roivainen

News | PET Imaging | April 19, 2021
April 19, 2021 — The preliminary...
#NorthStar Medical #Radioisotopes, LLC, a global innovator in the development, production and commercialization of #radiopharmaceuticals used for #medicalimaging and #therapeutic applications, announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.

NorthStar Medical Radioisotopes, Beloit, Wisconsin campus (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | April 16, 2021
April 16, 2021 — ...

Scan of brain of someone who did not develop TTS. Image courtesy of European Heart Journal

News | PET-CT | March 29, 2021
March 29, 2021 — Heightened activity in the brain, caused by stressful events, is linked to the risk of developing a
Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. Image courtesy of Shine Medical Technologies

News | Radiopharmaceuticals and Tracers | March 26, 2021
March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of